Huons Group’s North American subsidiary, Huons USA, participated in the recent CPHI Americas trade show held in Philadelphia, Pennsylvania, revealing the company’s major pharmaceuticals and promising pipeline candidates.
Represented by CEO Choi Jae-myeong, Huons USA showcased the group’s comprehensive portfolio, including products from Huons, Huons Lab, and PanGen, emphasizing their integrated offerings to a global audience.
The event, which attracted over 500 participants from more than 50 countries across the pharmaceutical and biotech sectors, served as a crucial platform for Huons USA to increase its international visibility.
During the exhibition, the company focused on promoting its core product lineup, especially injections and eye drops. Notably, Huons’ newly approved multi-use lidocaine formulations (1% and 2% in 20mL bottles), which recently received FDA approval in the United States, garnered significant attention from attendees.
In addition, Huons USA introduced PanGen’s biosimilar erythropoietin (EPO) products and shared information about its contract development and manufacturing organization (CDMO) services. The pipeline development of HyDIFFUZETM, a platform technology that converts intravenous (IV) hyaluronidase to subcutaneous (SC) injections, was also highlighted.
Throughout the event, Huons USA engaged in active discussions with buyers from North and South America, the Middle East, Asia, and Africa, fostering potential collaborations and expanding export opportunities.
CEO Choi Jae-myeong stated, “Our participation at CPHI Americas was focused on enhancing Huons Group’s global recognition and promoting our advanced pharmaceutical products. We aim to build strategic partnerships and expand exports through active engagement with international stakeholders.”
